1,451 AI Medical Devices Approved in the U.S.

5 min Read Time

The U.S. Food and Drug Administration (FDA) has approved exactly 1,451 AI-powered medical devices through the end of 2025 – 295 of them alone in the past year. In Europe, there isn’t even a comparable public database. While U.S. hospitals routinely deploy AI diagnostics, German hospitals rely on isolated, bespoke solutions – and wait for the AI Act, whose high-risk requirements won’t take effect until 2027. A status report.

What is Ai-powered?

Ai-powered is a concrete priority for companies in 2026 because it directly shapes digital care processes, privacy requirements and hospital IT. This article uses synaforce as an example to show which requirements, figures and operational steps matter in practice.

295 approvals in one year: What the FDA numbers reveal

Since 2017, the FDA has maintained a publicly accessible database of all AI-powered medical devices granted market authorization. The figures show an unmistakable trend: from 29 approvals in 2017 to 295 in 2025 – a record that decisively surpassed the previous year’s high of 223.

76% of all approved AI devices serve radiology – a domain where pattern recognition on large image datasets excels. GE HealthCare tops the rankings with 120 approvals, followed by Siemens Healthineers with 89. That two of the top three manufacturers have European roots only underscores the regulatory asymmetry between the U.S. and the EU.

Yet not every approval signals clinical value. An analysis published in JAMA Network Open (April 2025) examined 903 FDA-cleared AI medical devices – and delivered a sobering verdict: 24.1% lacked any clinical validation study. Only 2.4% had undergone randomized controlled testing; 8.1% were evaluated prospectively. Roughly 90% of these devices relied solely on retrospective data – or no clinical evidence whatsoever.

That means the FDA’s tally of 1,451 approvals is impressive as a barometer of market momentum – but only a limited indicator of quality. For hospital procurement teams evaluating an AI system, FDA clearance alone is insufficient. What matters are prospective studies conducted on comparable patient populations – and transparent, reproducible clinical validation within their own care environment.

Europe’s blind spot: No database, no transparency

In Europe, no equivalent public list exists. Neither the European Medicines Agency (EMA) nor Germany’s Federal Institute for Drugs and Medical Devices (BfArM) maintains an accessible database of certified AI medical devices. The EU’s intended transparency tool – EUDAMED – has been under development for years. Individual modules will become mandatory starting in May 2026, but a complete overview of all AI products on the European market won’t be available for several more years.

Independent trackers estimate at least 219 CE-marked AI medical devices are already on the market (as of January 2025). The true number is likely higher – but nobody knows for sure. For hospital buyers weighing which AI system to evaluate, that’s a real operational problem.

DACH hospitals deploy AI – but in siloed solutions

Despite regulatory gaps at the European level, individual DACH hospitals are already using AI diagnostics in routine clinical practice. Results are promising – but remain fragmented.

Asklepios, one of Germany’s largest private hospital operators, has installed the Israeli AI system Aidoc in over 25 hospitals. The software analyzes CT scans in real time, flagging strokes, intracranial hemorrhages, and vertebral fractures – funded via KHZG innovation grants. Its key advantage? Aidoc reprioritizes radiologists’ worklists so time-critical cases appear at the top – not buried in the queue.

The largest prospective study on AI use in diagnostics also originates in Germany. Published in Nature Medicine, the Vara-PRAIM study analyzed over 463,000 mammography screenings – and found a 17.6% increase in breast cancer detection, alongside reduced workload for radiologists. It remains the world’s largest prospective trial of its kind.

“The question is no longer whether AI works in diagnostics. The question is how we bridge the gap from research into routine clinical practice – regulatorily, organizationally, and economically.”
– Prof. Alexander Berens, University of Tübingen (press release, 2025)

The problem? Each implementation is a standalone project. There is no national standard for integrating AI into hospital information systems, no unified interface, and no central registry tracking which clinic uses which system. Although Germany’s Innovation Fund (G-BA) supports the xR.AI project to promote standardized AI use in radiology, nationwide rollout remains distant.

The consequence? German hospitals seeking to introduce AI diagnostics must navigate every step themselves – from product selection and integration into their hospital information system (KIS), to training radiologists. Added complications include unresolved liability questions, neither settled nationally nor at the EU level. If an AI system misses a finding – and the treating physician relies on it – who bears responsibility? The Medical Device Regulation (MDR) governs manufacturer product liability, but physicians’ duty of care remains unchanged. In practice, this legal ambiguity leads many radiologists to treat AI findings not as decision-making inputs, but merely as supplementary hints.

AI Act takes effect in 2027: What lies ahead for MedTech companies

The EU AI Act entered into force in August 2024 – but medical devices benefit from a transition period: full high-risk requirements apply only from 2 August 2027 onward. AI systems classified as medical devices under the MDR or IVDR are automatically designated as high-risk AI.

What does that mean in practice? Manufacturers must implement AI-specific risk management systems, meet stringent data quality and data governance standards, produce technical documentation exceeding MDR requirements, and embed mechanisms for human oversight. The burden is substantial – especially for smaller firms.

A silver lining: In November 2025, the European Commission proposed an omnibus simplification package aimed at reducing overlap between the AI Act and the MDR/IVDR. Instead of duplicate documentation and dual conformity assessments, a single integrated process is envisioned. Adoption is expected by summer 2026.

For German MedTech SMEs – 93% of the sector employs fewer than 250 people – this isn’t academic. Over recent years, the MDR has already driven some manufacturers to withdraw products from the European market because certification costs outweighed revenue. If the AI Act layers similar bureaucracy on top, consolidation will accelerate.

At the same time, regulation creates a quality advantage: AI medical devices compliant with both the MDR and the AI Act gain a trust premium over FDA-only cleared devices. European manufacturers who clear both hurdles can leverage that dual compliance as a differentiator in global markets – provided they survive the transition phase financially and operationally through 2027.

Accelerate – or fall behind

The global AI-in-healthcare market stood at an estimated $21.66 billion in 2025. By 2030, it’s projected to exceed $110 billion – a compound annual growth rate (CAGR) of 38.6% (MarketsandMarkets). PwC Strategy& estimates Europe’s potential at $203 billion by 2030.

Germany hosts strong AI players in MedTech – including Siemens Healthineers, Brainomix, Vara, and Merantix. Clinical research operates at international standards – the PRAIM study proves that emphatically. What’s missing is the bridge from research to routine care: a European AI database delivering transparency; a harmonized approval process that doesn’t overwhelm SMEs; and a hospital landscape that treats AI not as a grant-funded pilot, but as a standard clinical tool.

In eight years, the FDA has approved 1,451 AI medical devices – and learned to adapt its processes along the way. Europe, in the same timeframe, drafted a regulation whose impact won’t begin until 2027. Anyone who fails to see that lag as a strategic risk hasn’t grasped the market’s velocity.

Frequently Asked Questions

Header Image Source: Pexels / MART PRODUCTION (px:7089623)